Linda's First Quilt
Now in Alaska, I think
Melisas Thrall earned a Rivkin Center Scientific Scholar
award in 2010. She has been with the
University of Washington Medical School since 2009 as a Fellow of the
Department of Gynocolgical Oncology ; previously she seems to have practiced in
Page, Arizona. Dr. Thrall has published
three important papers involving ovarian cancer since her award date, and they
have been fairly heavily cited – indicating that her research has important
implications. I count eleven research
papers published under her name since
she obtained her M.D. degree, in 2001.
The research supported by the Rivkin Center was presented under
the title “A population based evaluation of the use and outcome of neoadjuvant
chemotherapy”. Don’t
hang up now! I will
explain. “Adjuvant” is merely
medico-speak for “helping”, and neoadjuvant therapy is therapy administered
before the main event; for instance, chemo before a debulking (cancer-removing)
operation. Dr. Thrall’s citation states
that “the current standard of care for advanced stage ovarian cancer involves
surgery with a maximal effort to remove all visible tumor, followed by the
administration of platinum based chemotherapy”. This describes Linda’s treatment exactly,
insofar as I understand it. However, it
seems to be the case that not all women are treated according to this precise
formula. Dr. Thrall intends to evaluate outcomes,
using a “large population-based sample of patients treated in the last ten
years”. Between the Hutch and the MRC,
such records are available – attesting to the great and growing importance of
data-bases and the people who understand them.
I am impressed by Dr. Thrall’s record and evident abilities,
and I am encouraged to find people like her fighting the disease that took my
wife. I do admit to being a little
confused, however. The title of her
proposal implies that she will study the efficacy of neoadjuvant chemotherapy –
that is, chemo before surgery. Do they
do that? Under what circumstances do
they do it? I’m curious, although I
probably wouldn’t understand the explanation!
Yeah, I know – this was boring, even if important. Enjoy the picture.
More on neoadjuvant chemo. I wish this orotocol had been in place five years ago.
ReplyDeletehttp://www.curetoday.com/articles/sgo-asco-issue-new-guidelines-for-ovarian-cancer-treatment